Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MN-001 in Interstitial Cystitis
NCT00295854Phase 2Completed
- Sponsor
- MediciNova, Inc.
- Start
- May 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tipelukast in interstitial cystitis (IC) (3 arms), sponsored by MediciNova, Inc. Primary endpoint: Percentage of Patients at Least 'Moderately Improved' on Global Response Assessment at 8 weeks. Started May 2005; status: completed.
02
Drugs
tipelukast
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT00295854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295854.